PMID- 24613367
OWN - NLM
STAT- MEDLINE
DCOM- 20141218
LR  - 20220330
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 173
IP  - 2
DP  - 2014 May 1
TI  - Positive effect of intravenous iron-oxide administration on left ventricular 
      remodelling in patients with acute ST-elevation myocardial infarction - a 
      cardiovascular magnetic resonance (CMR) study.
PG  - 184-9
LID - S0167-5273(14)00369-6 [pii]
LID - 10.1016/j.ijcard.2014.02.016 [doi]
AB  - OBJECTIVES: This study investigated the safety profile and potential 
      "therapeutic" effect of intravenous ultrasmall superparamagnetic iron-oxide 
      (USPIO)-based iron administration regarding infarct healing in patients with 
      ST-elevation myocardial infarction (STEMI). USPIO-administration was recently 
      shown to enable an improved characterization of myocardial infarct pathology in 
      acute STEMI patients. MATERIALS AND METHODS: Seventeen study patients (IRON, 54 +/- 
      9 yrs, 88% male) and 22 matched controls (CONTROL, 57 +/- 9 yrs, 77% male) both 
      with primary reperfused STEMI underwent multi-parametric CMR studies in the first 
      week and three months after acute MI. Only IRON patients received a single 
      intravenous bolus of 510 mg elemental iron as ferumoxytol (Feraheme(TM)) within 
      four days following acute MI. RESULTS: Three months later, all patients were 
      alive and there were no adverse cardiac events. Significant improvement in left 
      ventricular (LV) ejection fraction (IRON: 53 +/- 10% to 59 +/- 9%, p=0.002; CONTROL: 
      54 +/- 6% to 57 +/- 10%, p=0.005) as well as shrinkage of infarct size were seen in 
      both groups at follow-up. There was a more pronounced decrease in infarct size in 
      the IRON group (IRON: -10.3 +/- 5.4% vs. CONTROL: -7.0 +/- 8.4%, p=0.050) in addition 
      to a significant decrease in both endocardial extent and prevalence of transmural 
      infarctions in IRON but not in CONTROL patients. A significant decrease in LV end 
      systolic volume was only seen in the IRON group (71 +/- 25 mL to 59 +/- 25 mL, 
      p=0.002). CONCLUSIONS: Intravenous iron administration in acute STEMI patients 
      seems to be associated with an improved infarct healing and a beneficial global 
      left ventricular remodelling. These findings together with the good safety 
      profile make USPIO-based iron administration a promising future candidate as a 
      "diagnostic" and "therapeutic" adjunctive solution in acute MI management.
CI  - Copyright (c) 2014 Elsevier Ireland Ltd. All rights reserved.
FAU - Florian, Anca
AU  - Florian A
AD  - Department of Cardiology and Angiology, University Hospital Munster, Munster, 
      Germany.
FAU - Ludwig, Anna
AU  - Ludwig A
AD  - Division of Cardiology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
FAU - Rosch, Sabine
AU  - Rosch S
AD  - Division of Cardiology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
FAU - Yildiz, Handan
AU  - Yildiz H
AD  - Division of Cardiology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
FAU - Klumpp, Siegfried
AU  - Klumpp S
AD  - Pharmacy, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
FAU - Sechtem, Udo
AU  - Sechtem U
AD  - Division of Cardiology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
FAU - Yilmaz, Ali
AU  - Yilmaz A
AD  - Department of Cardiology and Angiology, University Hospital Munster, Munster, 
      Germany. Electronic address: ali.yilmaz@ukmuenster.de.
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140222
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Contrast Media)
RN  - 0 (Dextrans)
RN  - 0 (Magnetite Nanoparticles)
RN  - 0 (ferumoxtran-10)
SB  - IM
CIN - Int J Cardiol. 2014 Jun 1;174(1):226. PMID: 24767753
MH  - Aged
MH  - Contrast Media/administration & dosage/adverse effects
MH  - Dextrans/*administration & dosage/*adverse effects
MH  - Electrocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Injections, Intravenous
MH  - *Magnetic Resonance Imaging, Cine
MH  - Magnetite Nanoparticles/*administration & dosage/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnosis/*drug therapy/physiopathology
MH  - Treatment Outcome
MH  - Ventricular Function, Left/drug effects
MH  - Ventricular Remodeling/*drug effects
OTO - NOTNLM
OT  - CMR
OT  - Ferumoxytol
OT  - LGE
OT  - Myocardial infarction
OT  - USPIO
OT  - Ventricular remodelling
EDAT- 2014/03/13 06:00
MHDA- 2014/12/19 06:00
CRDT- 2014/03/12 06:00
PHST- 2013/09/19 00:00 [received]
PHST- 2014/01/28 00:00 [revised]
PHST- 2014/02/13 00:00 [accepted]
PHST- 2014/03/12 06:00 [entrez]
PHST- 2014/03/13 06:00 [pubmed]
PHST- 2014/12/19 06:00 [medline]
AID - S0167-5273(14)00369-6 [pii]
AID - 10.1016/j.ijcard.2014.02.016 [doi]
PST - ppublish
SO  - Int J Cardiol. 2014 May 1;173(2):184-9. doi: 10.1016/j.ijcard.2014.02.016. Epub 
      2014 Feb 22.